Tempest Therapeutics, Inc. has entered into a master clinical supply agreement with F. Hoffmann-La Roche Ltd. where Roche will provide its drug atezolizumab for use in clinical studies involving Tempest's compound amezalpat. Additionally, the company has amended its Rights Agreement, extending the Final Expiration Date to after the 2025 Annual Meeting of Stockholders or to October 2026 if stockholders approve the Rights Plan. Tempest has issued a press release announcing these updates.
Proper names mentioned: - Tempest Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Computershare Trust Company, N.A.